DSP-0038 is a serotonin receptor modulator that acts as a 5-HT2A receptor antagonist and 5-HT1A receptor agonist. It is under development for psychosis related to Alzheimer's disease. The drug was developed using artificial intelligence that enabled it to proceed from discovery to Phase I trial in one year, compared to an industry average of 4–6 years.[1][2][3][4]
References
edit- ^ Brady, Linda S.; Lisanby, Sarah H.; Gordon, Joshua A. (2023). "New directions in psychiatric drug development: promising therapeutics in the pipeline". Expert Opinion on Drug Discovery. 18 (8): 835–850. doi:10.1080/17460441.2023.2224555. ISSN 1746-0441.
- ^ Lv, Qi; Zhou, Feilong; Liu, Xinhua; Zhi, Liping (2023). "Artificial intelligence in small molecule drug discovery from 2018 to 2023: Does it really work?". Bioorganic Chemistry. 141: 106894. doi:10.1016/j.bioorg.2023.106894.
- ^ Mak, Kit-Kay; Balijepalli, Madhu Katyayani; Pichika, Mallikarjuna Rao (2022). "Success stories of AI in drug discovery - where do things stand?". Expert Opinion on Drug Discovery. 17 (1): 79–92. doi:10.1080/17460441.2022.1985108.
- ^ Philippidis, Alex (1 January 2023). "BMS Collaboration Paying Off for Exscientia: AI drug developer designs EXS4318, the I&I small molecule that has entered Phase I trials overseen by pharma giant in up-to-$1.3B+ partnership". GEN Edge. 5 (1): 147–150. doi:10.1089/genedge.5.1.31.